Brief: Moonlake Immunotherapeutics To Initiate Global Phase 2 Study Of Nanobody® Sonelokimab In Patients With Active Psoriatic Arthritis
26/09/2022 14:35
Sept 26 (Reuters) - MoonLake Immunotherapeutics
MLTX.O :
* MOONLAKE IMMUNOTHERAPEUTICS TO INITIATE GLOBAL PHASE 2
STUDY OF
NANOBODY® SONELOKIMAB IN PATIENTS WITH ACTIVE PSORIATIC
ARTHRITIS
* MOONLAKE IMMUNOTHERAPEUTICS-TO ENROLL ABOUT 200 PATIENTS
IN THE
U.S. AND EUROPE TO ASSESS EFFICACY AND SAFETY OF SONELOKIMAB
COMPARED TO PLACEBO
Source text for Eikon: ID:nGNX5HbdcP
Further company coverage: MLTX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial